Benefit of Moderate Intensity Exercise in Patients With Clinical Quiescent Inflammatory Bowel Disease

Inclusion criteria

• Patients diagnosed with Crohn's disease or Ulcerative colitis.
• Aged between 18 and 65 years.
• Disease must be in clinical remission for at least 2 months prior to study enrollment, as defined by: Crohn's disease: Harvey-Bradshaw Index < 5 Ulcerative colitis: Mayo Ulcerative Colitis Subscore < 2
• Not currently receiving corticosteroids,
• If receiving immunomodulators or biologic therapy, the treatment regimen must be stable for at least 2 months prior to enrollment.
• Participants must have access to and be capable of using online communication tools and digital platforms.

Exclusion criteria

• Patients with medical conditions that limit the ability to exercise, including Severe joint pain or inflammatory arthritis affecting ambulation or mobility Advanced cardiac disease (New York Heart Association Class ≥ 2) Chronic lung disease or pulmonary hypertension Liver cirrhosis Chronic kidney disease stage 3 or higher

Poorly controlled non-communicable diseases, such as:

Hypertension (BP ≥ 160/100 mmHg) Diabetes mellitus with poor glycemic control (HbA1c ≥ 9% or requiring insulin therapy)

• Patients who already engage in moderate-intensity exercise for more than 60 minutes per week on a regular basis.
• Pregnant individuals or those planning to become pregnant during the study period.
• Patients planning to undergo treatment changes or surgery within the next 3 months, or who have had surgery within the past 6 months.